ArticleFrontiers in oncology2026
Immune checkpoint inhibitor-induced inflammatory arthritis as a potential biomarker for long-term response to tislelizumab in advanced head and neck carcinoma: a case report and literature review.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have emerged as promising treatment strategies in cancer immunotherapy. However, a significant proportion of patients do not respond to these therapies, underscoring the need for reliable biomarkers of treatment responsiveness. Although a potential correlation between the development of immune-related adverse events (irAEs) and favorable response to ICI therapy has been demonstrated, the predictive reliability of irAEs for treatment efficacy remains to be fully established. Case summary: This report presents a case of advanced unknown primary carcinoma of the head and neck (UPCHN) with rapid disease progression following initial treatment with neck dissection and concurrent chemoradiotherapy. Subsequent administration of a weekly regimen comprising paclitaxel, carboplatin, and cetuximab (PCC) resulted in complete response (CR). Maintenance therapy with cetuximab and tislelizumab was then initiated. After 20 months of sustained CR, the patient developed grade 3 ICI-induced inflammatory arthritis (ICI-IA), necessitating discontinuation of ICI therapy. Notably, the patient remained in complete remission for over 1 year following cessation of ICI therapy, with no clinical or radiographic evidence of tumor progression. Conclusion: This case suggests that the development of ICI-IA reflects an immune hyperactivated state that correlates with long-term antitumor response to tislelizumab. The sustained remission observed in this patient following ICI discontinuation highlights the potential role of irAEs, particularly ICI-IA, as a potential biomarker of ICI efficacy. Further prospective, large-scale studies are warranted to validate these findings and assess their clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.